|
May 1
|
'Declare victory and move on': Eli Lilly CEO on Trump tariff threat
|
|
May 1
|
Pharma downplays tariff threat, even as risks remains unclear
|
|
May 1
|
If A Recession Hits, Will Medical Stocks Be A Safe Haven For Investors — Again?
|
|
May 1
|
FDA approves J&J’s Imaavy for generalised myasthenia gravis
|
|
May 1
|
The Zacks Analyst Blog Highlights Amazon, Johnson & Johnson, Cisco Systems and NeurAxis
|
|
May 1
|
Trump Says Tariffs Politically Risky, But He’s Not Rushing Deals
|
|
Apr 30
|
Top Stock Reports for Amazon.com, Johnson & Johnson & Cisco Systems
|
|
Apr 30
|
Johnson & Johnson (JNJ): Jim Cramer Says “They Love the Weak Dollar” — Is This Quiet Giant Back in Favor?
|
|
Apr 30
|
Is Johnson & Johnson (JNJ) the Best Dow Stock for the Next 12 Months?
|
|
Apr 30
|
Johnson & Johnson (NYSE:JNJ) Gains FDA Approval For IMAAVY™ To Treat Myasthenia Gravis
|
|
Apr 30
|
Johnson & Johnson receives FDA approval for IMAAVY™ (nipocalimab-aahu), a new FcRn blocker offering long-lasting disease control in the broadest population of people living with generalized myasthenia gravis (gMG)
|
|
Apr 29
|
4 PFA studies in the spotlight at Heart Rhythm 2025
|
|
Apr 29
|
Johnson & Johnson (JNJ): Among the Best Long-Term Dividend Stocks to Buy According to Billionaires
|
|
Apr 28
|
Stocks Rise in Final Hour of Wall Street Trading: Markets Wrap
|
|
Apr 28
|
Johnson & Johnson (JNJ): Among the Most Profitable Blue Chip Stocks to Buy Now
|
|
Apr 28
|
Google Parent Alphabet Leads US High-Grade Issuance Rush
|
|
Apr 28
|
CG Oncology Soars On Its Johnson & Johnson-Rivaling Cancer Drug
|
|
Apr 28
|
New data from J&J’s bladder cancer drug-device trial strengthens support for NDA
|
|
Apr 28
|
Jim Cramer Says Trump Administration Should Intervene in Johnson & Johnson (JNJ) Legal Issues – ‘Where Are Capitalist Instincts Here?’
|
|
Apr 28
|
J&J’s Tremfya gains EC marketing authorisation for ulcerative colitis
|